PubblicazionI

Pubblicazioni su riviste/libri non recensiti

– Crucitta E., Locopo N., Lorusso V., Lasalandra C., Attolico M., Sambiasi D., Mazzei A., De Lena M. “Nuovi inibitori dell’enzima aromatasi nel trattamento del carcinoma della mammella avanzato” Folia Oncologica, 22: 3-10, 1999

– Brandi M, Longo S, Sambiasi D, Schittulli F.
“Nuovi approcci farmacologici nel management pre- e post-operatorio dei tumori della mammella”  International Trends in Oncology Aprile 2008

– Domenico Sambiasi, Rita Calabrese, Ludovico Balducci “Cancro e Spiritualità”
 Neoplasie dell’Anziano – vol. 2 cap. 47

 

Pubblicazioni su riviste recensite
(Impact Factor; Journal Citation Reports – 2012 by Institute for Scientific Information)

– Crucitta E., Lorusso V., Attolico M., Sambiasi D., Mazzei A. and De Lena M. New aromatase inhibitors in the treatment of advanced breast cancer. (Review) International Journal of Oncology, 17 (5): 1037-1041, 2000  I.F. 1.381

– De Lena M., Lorusso V., Latorre A., Fanizza G., Gargano G., Caporusso L., Guida M., Catino A., Crucitta E., Sambiasi D. and Mazzei A.
Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study.
European Journal of Cancer, 37 (3): 364-368, 2001 I.F. 2.725

– Guida M., Cramarossa A., Gentile A., Benvestito S., De Fazio M., Sambiasi D., Crucitta E. and
De Lena M.
Metastatic malignant melanoma of the gallbladder: a case report and review of the literature. Melanoma Research, 12: 1-7, 2002 I.F. 1.862

– Lorusso V., Crucitta E, Silvestris N., Catino A., Caporusso L., Mazzei A., Guida M., Latorre A.,
Sambiasi D., D’Amico C., Schittulli F., Calabrese P., De Lena M.
Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. British Journal of Cancer, 88 (4): 491-5, 2003 I.F. 3.639

– Latorre A, De Lena M, Catino A, Crucitta E, Sambiasi D, Guida M, Misino A, Lorusso V.
Epithelial ovarian cancer: Second and third line chemotherapy (Review).
International Journal of Oncology, 21 (1):179-86, 2002 I.F. 2.330

– Lorusso V, Crucitta E, Panza N, Silvestris N, Guida M, Carpagnano F, Mancarella S, Sambiasi D,
De Lena M
Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer.  Annals of Oncology, 13 (12):1862-7, 2002 I.F. 3.153

– Catino A, Crucitta E, Latorre A, Sambiasi D, Calabrese P, Lorusso V.
Amifostine as chemoprotectant in metastatic breast cancer patients treated with doxorubicin. Oncology Reports 10 (1):163-7,2003 I.F. 1.171

– Portalone L, Antilli A, Nunziati F, Crispino C, De Marinis F, Friggeri L, Lombardi A, Lorusso V, Pronzato P, Sambiasi D, e Signora M
Epirubicin and gemcitabine as first-line treatment in malignant pleural Mesothelioma.
Tumori 91:15-18, 2005 I.F. 0.631

– Lorusso V, Spada M, Giampaglia M, Misino A, Calabrese R, Latorre A, Monticelli G, Guida M, Sambiasi D, Colucci G; Gruppo Oncologico dell'Italia Meridionale.
Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale).  Annals of Oncology 2006 Jun;17 Suppl 7:vii15-7. I.F. 4.319

– S. De Summa, R. Pinto, D. Sambiasi, D. Petriella, V. Paradiso, A. Paradiso & S. Tommasi*
BRCAness: a deeper insight into basal-like breast tumors
 Annals of Oncology 2013 24 (Supplement 8): viii13–viii21 doi:10.1093 I.F. 7.384

– B.Pilato, S. De Summa, K. Danza, R. Lacalamita, R. Lambo, D. Sambiasi, A. Paradiso and S. Tommasi. Genetic risk transmission in a family affected by familial breast cancer
Journal of Human Genetics (2013), 1–3 I.F. 2.365

– Sambiasi D, L. Rossana, B. Pilato, S. Tommasi, G. Trojano, A. Kardhashi, M. Digennaro, V. Trojano, G. Simone, A. Paradiso.
BRCA1/2 and clinical outcome in a monoinstitutional cohort of hereditary breast cancer women Oncology Reports 2014 31:365-369 doi:10.3892 I.F. 2.297

– S De Summa, R Pinto, B Pilato, D Sambiasi, L Porcelli, G Guida, E Mattioli, A Paradiso, G Merla, L Micale, P De Nittis and S Tommasi* 
Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer
Cell Death & Disease (2014) 5, e1076; doi:10.1038/cddis.2014.30 I.F. 6.044

– Schirosi L, De Summa S, Tommasi S, Paradiso A, Sambiasi D, Popescu O, Simone G, Mangia A. Immunoprofile from tissue microarrays to stratify familial breast cancer patients.
Oncotarget. 2015 Aug 3. I.F. 6.359

– Paradiso AV, Digennaro M, Sambiasi D, Comment on “The incidence of leukaemia in women with BRCA1 and BRCA2 mutations:  an International Prospective Cohort Study”. Br J Cancer. 2016 Aug 23;115(5):e3. doi: 10.1038/bjc.2016.224 I.F. 5.569

– Simone G, Diotaiuti S, Digennaro M, Sambiasi D, De Summa S, Tommasi S, Altieri R, Mangia A, Dantona C, Paradiso A.    Comment on “Renewed interest in the progesterone receptor in breast cancer”. Br J Cancer. 2017 Jul 11;117(2):e1. doi: 10.1038/bjc.2017.90  I.F. 5.569

– Digennaro M, Sambiasi D, Tommasi S, Pilato B, Diotaiuti S, Kardhashi A, Trojano G, Tufaro A, Paradiso AV. Hereditary and        non-hereditary branches of family eligible for BRCA test: cancers in other sites. Hered Cancer Clin Pract. 2017 May 25;15:7. doi: 10.1186/s13053-017-0067-8   I.F. 1.590

– De Summa S, Graziano F, Pilato B, Pinto R, Danza K, Lacalamita R, Serratì S, Sambiasi D, Grassi M, Tommasi S.                         Six low-penetrance SNPs for the estimation of breast cancer heritability: A family-based study in Caucasian Italian patients.         Oncol Lett. 2017 Oct;14(4):4384-4390. doi:10.3892/ol.2017.6725   I.F. 1.390

 

Comunicazioni a Congressi

  • Lorusso V., Crucitta E., Sambiasi D., Attolico M., Mancarella S., Mazzei A. and De Lena M. Mitoxantrone plus gemcitabine in advanced breast cancer. A phase II study.
Poster 236: 2nd European Breast Cancer Conference, Brussels 26-30 Sep 2000
  • Lorusso V., Crucitta E., Sambiasi D., Attolico M., Mazzei A. and De Lena M.
Docetaxel plus ifosfamide in advanced breast cancer refractory to anthracyclines: A phase II study.
Annals of Oncology, 11 (4): 36 (abstr. 154), 2000
  • A. Latorre, V. Lorusso, A. Catino, E. Crucitta, D. Sambiasi, L. Caporusso, M. Guida and M. De Lena. Topotecan and ifosfamide in the treatment of recurrent ovarian cancer: a phase II study. Preliminary results.
Annals of Oncology 12 (suppl 4): 35 (Abstr C18), 2001
  • L. Portalone, A. Antilli, A. Lombardi, Mauro Signora, F. Nunziati, F. De Marinis, C.Crispino, P. Pronzato, L. Friggeri, D. Sambiasi. 
Epirubicin and gemcitabine (EG) as first-line treatment in malignant pleural mesothelioma (MPM): An A.I.P.O. multicenter phase II trial.
Annals of Oncology (suppl 5): 13 (Abstract P549),2002